טוען...
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study
The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in fo...
שמור ב:
הוצא לאור ב: | Neuropsychopharmacology |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Nature Publishing Group
2017
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5312066/ https://ncbi.nlm.nih.gov/pubmed/27681442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2016.224 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|